Fecal Zonulin Elevated in Crohn’s Disease and Smokers
By LabMedica International staff writers Posted on 20 Nov 2017 |
Image: Enzyme-linked immunosorbent assay (ELISA) kits for the measurement of fecal and serum zonulin (Photo courtesy of DRG International).
Human zonulin is a protein that increases permeability in the epithelial layer of the small intestine by reversibly modulating the intercellular tight junctions. There is not sufficient information available about zonulin's participation in inflammatory bowel diseases (IBD).
Increased serum/plasma zonulin levels have been described in celiac disease, type 1 and 2 diabetes or in obesity-associated insulin resistance, and circulating plasma zonulin has been suggested as a potential marker of intestinal permeability. Fecal and serum zonulin have been investigated in IBD patients and its relation to the disease localization and behavior.
Scientists at Charles University (Prague, Czech Republic) enrolled 40 consecutive IBD patients, 32 with Crohn’s disease (CD) and eight with ulcerative colitis (UC) in whom fecal and blood samples were available from a tertiary IBD clinical center. Forty healthy persons (laboratory technicians and their family members) without personal or family history of IBD were matched by age and gender and examined as a control (CTRL) group. There were 27 active smokers and 13 non-smokers in the CTRL group.
Raw stool samples from the IBD and CTRL groups were frozen and stored at −80 °C within 12 hours after the sampling. The Fecal Sample Preparation kit for the preparation of fecal eluates was used. Blood samples were collected into commercially available serum-separating tubes. Fecal and serum zonulin concentrations were measured by competitive enzyme-linked immunosorbent assays (ELISA) as: Zonulin (Serum) EIA and Zonulin (Stool) EIA.
Fecal calprotectin as a marker of gut inflammation was measured by the Calprotectin Alegria ELISA kit. The investigators found that serum and fecal zonulin were significantly higher in patients with Crohn’s disease compared to ulcerative colitis. No association of serum or fecal zonulin was found with respect to IBD localization and behavior. The only difference was found with respect to smoking. Both the IBD cohort and healthy smokers showed significantly higher fecal zonulin levels (median 203 ng/mL) compared to non-smokers (median 35.8 ng/mL). Fecal calprotectin concentrations were significantly higher in IBD patients compared to healthy controls.
The authors concluded that zonulin as a marker of intestinal permeability is increased in stool and serum samples of patients with Crohn’s disease. However, zonulin levels in IBD patients are not influenced by disease location or behavior. High fecal zonulin levels in smokers with and without intestinal disease point to the significant and undesirable up-regulation of gut permeability in cigarette smokers. The study was published online on September 23, 2017, in the journal Practical Laboratory Medicine.
Related Links:
Charles University
Increased serum/plasma zonulin levels have been described in celiac disease, type 1 and 2 diabetes or in obesity-associated insulin resistance, and circulating plasma zonulin has been suggested as a potential marker of intestinal permeability. Fecal and serum zonulin have been investigated in IBD patients and its relation to the disease localization and behavior.
Scientists at Charles University (Prague, Czech Republic) enrolled 40 consecutive IBD patients, 32 with Crohn’s disease (CD) and eight with ulcerative colitis (UC) in whom fecal and blood samples were available from a tertiary IBD clinical center. Forty healthy persons (laboratory technicians and their family members) without personal or family history of IBD were matched by age and gender and examined as a control (CTRL) group. There were 27 active smokers and 13 non-smokers in the CTRL group.
Raw stool samples from the IBD and CTRL groups were frozen and stored at −80 °C within 12 hours after the sampling. The Fecal Sample Preparation kit for the preparation of fecal eluates was used. Blood samples were collected into commercially available serum-separating tubes. Fecal and serum zonulin concentrations were measured by competitive enzyme-linked immunosorbent assays (ELISA) as: Zonulin (Serum) EIA and Zonulin (Stool) EIA.
Fecal calprotectin as a marker of gut inflammation was measured by the Calprotectin Alegria ELISA kit. The investigators found that serum and fecal zonulin were significantly higher in patients with Crohn’s disease compared to ulcerative colitis. No association of serum or fecal zonulin was found with respect to IBD localization and behavior. The only difference was found with respect to smoking. Both the IBD cohort and healthy smokers showed significantly higher fecal zonulin levels (median 203 ng/mL) compared to non-smokers (median 35.8 ng/mL). Fecal calprotectin concentrations were significantly higher in IBD patients compared to healthy controls.
The authors concluded that zonulin as a marker of intestinal permeability is increased in stool and serum samples of patients with Crohn’s disease. However, zonulin levels in IBD patients are not influenced by disease location or behavior. High fecal zonulin levels in smokers with and without intestinal disease point to the significant and undesirable up-regulation of gut permeability in cigarette smokers. The study was published online on September 23, 2017, in the journal Practical Laboratory Medicine.
Related Links:
Charles University
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines